comparemela.com

Latest Breaking News On - Chikungunya virus - Page 5 : comparemela.com

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. Immunogenicity data for the trial are expected in November 2023. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in collaboration with Instituto Butantan, the VLA1553-321 adolescent trial is intended to su

CHIKV vaccine fever on rise as Valneva phase III follows Bavarian Nordic data

About two weeks after chikungunya virus (CHIKV) vaccine contender Bavarian Nordic A/S provided phase III data with its prospect, rival Valneva SE rolled out positive phase III safety findings in adolescents with its single-dose candidate VLA-1553. Results from the Saint-Herblain, France-based company’s first trial in an endemic area with people previously infected with CHIKV showed the product was generally safe and well-tolerated in subjects aged 12-17 years, regardless of previous infection by the mosquito-borne disease, carried mainly by Aedes aegypti and Aedes albopictus. Immunogenicity data from the study are expected in November.

Chikungunya virus: New study uncovers Chikungunya virus unique invisibility shield that can help in developing effective vaccines

Chikungunya fever, a mosquito-borne disease, can spread directly from cell to cell, scientists have discovered. They found the virus can hijack the proteins that support cells and maintain their shape, causing the infected cell to reach out, make contact with and infect its neighbours. Symptoms can persist for months or years.

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

Saint-Herblain (France), August 14, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA) action date for the Biologics License Application (BLA) for VLA1553, Valneva’s chikungunya virus vaccine candidate, from the previously communicated end of August to the end of November. The FDA extended the PDUFA date to allow sufficient time to align and agr

What can mosquitoes and ticks carry? - The County Press

What can mosquitoes and ticks carry? - The County Press
mihomepaper.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mihomepaper.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.